PM
NVLN

Prosight Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Prosight Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-444,068
Closed -$1.31M – 40
2018
Q3 		$1.31M Buy
444,068
+249,405
+128% +$883K 0.73% 28
2018
Q2 		$716K Sell
194,663
-38,340
-16% -$154K 0.52% 27
2018
Q1 		$816K Sell
233,003
-63,485
-21% -$269K 0.51% 28
2017
Q4 		$925K Buy
+296,488
New +$1.43M 0.68% 27

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's NVLN Position: Q4 2018 in Review

Prosight Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 444,068 shares — an estimated $1.31M sold.

Prosight Management first reported a position in NVLN in Q4 2017 and held it in 4 quarters. The position peaked at $1.31M in Q3 2018. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

  • Prosight Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
  • Prosight Management sold 444,068 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $1.31M.
  • Prosight Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 4 quarters.
  • Prosight Management's Novelion Therapeutics Inc. Common Shares position peaked at $1.31M in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Prosight Management's 13F filing for Q4 2018, filed 14 Feb 2019.